Clinical Trial Update: Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 safety study of Imexon in combination with Gemcitabine in untreated pancreatic adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Imexon (imexon)

Snippet

Sponsor: AmpliMed Corporation | Conditions: Pancreatic Adenocarcinoma | Phase 1 | Status: COMPLETED